Johnson & Johnson $JNJ Shares Sold by Carnegie Investment Counsel

Key Points

• Carnegie Investment Counsel reduced its Johnson & Johnson stake by 4.3% in the third quarter, selling 5,650 shares and retaining 126,462 shares valued at approximately $33.48 million. Institutional investors collectively own 69.55% of JNJ.
• Company insiders sold $17.27 million worth of shares over the past 90 days, including sales by executives Jennifer Taubert and Elizabeth Forminard. Insiders now own just 0.16% of the company.
• Johnson & Johnson exceeded quarterly earnings expectations with $2.59 in EPS and $25.40 billion in revenue, while revenue rose 5.9% year over year. The company declared a quarterly dividend of $1.34 per share, equivalent to a 2.0% yield, and analysts maintain a “Moderate Buy” consensus with a $275.92 average price target.

Carnegie Investment Counsel cut its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 4.3% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 126,462 shares of the company's stock after selling 5,650 shares during the period. Carnegie Investment Counsel's holdings in Johnson & Johnson were worth $33,480,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in JNJ. Outlook Capital Management LLC acquired a new position in shares of Johnson & Johnson during the 2nd quarter worth about $28,000. Matrix Trust Co lifted its stake in Johnson & Johnson by 56.2% in the 2nd quarter. Matrix Trust Co now owns 150 shares of the company's stock valued at $38,000 after buying an additional 54 shares in the last quarter. Montgomery Financial Services LLC acquired a new stake in Johnson & Johnson in the 2nd quarter worth about $43,000. Polaris Financial Partners acquired a new stake in Johnson & Johnson in the 3rd quarter worth about $56,000. Finally, Bullseye Investment Management LLC purchased a new stake in Johnson & Johnson during the 2nd quarter worth approximately $63,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Jennifer Taubert sold 15,000 shares of the company's stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the sale, the executive vice president directly owned 194,451 shares in the company, valued at $51,210,615.36. This represents a 7.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Elizabeth Forminard sold 15,918 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total value of $4,090,926.00. Following the completion of the sale, the executive vice president directly owned 16,994 shares of the company's stock, valued at approximately $4,367,458. This represents a 48.37% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 64,515 shares of company stock worth $17,271,766 over the last ninety days. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Performance

JNJ opened at $267.67 on Friday. The firm has a market capitalization of $645.05 billion, a PE ratio of 24.20, a PEG ratio of 2.55 and a beta of 0.21. Johnson & Johnson has a twelve month low of $184.66 and a twelve month high of $281.07. The firm's 50-day moving average price is $265.57 and its 200 day moving average price is $250.11. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating analysts' consensus estimates of $2.53 by $0.06. The company had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.54%. Johnson & Johnson's quarterly revenue was up 5.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, sell-side analysts expect that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be issued a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson's payout ratio is currently 81.21%.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Positive sector rotation: JNJ is benefiting from fresh demand for defensive healthcare stocks, alongside gains in Procter & Gamble and Coca-Cola. Investors appear to be favoring companies with relatively stable demand and cash flows amid broader market pressure. Procter & Gamble Jumps as Defensive Buyers Enter
• Positive Sentiment: Medical-device progress: Johnson & Johnson reported real-world data for its VARIPULSE Pro platform and 12-month outcomes for the OMNYPULSE platform in atrial-fibrillation treatment. The results could support adoption of its electrophysiology portfolio and provide another growth avenue beyond pharmaceuticals. Johnson & Johnson Reports VARIPULSE and OMNYPULSE Data
• Positive Sentiment: Drug growth and guidance: Recent coverage highlights stronger pharmaceutical performance and Johnson & Johnson’s higher 2026 outlook, with projected sales of approximately $101.2 billion at the midpoint. The company also maintains a 64-year record of annual dividend increases, reinforcing its appeal to income-focused investors. Johnson & Johnson Drugs Lift Guidance
• Neutral Sentiment: Mixed business outlook: One business is advancing strongly while another has stalled, leaving investors focused on whether new growth can justify JNJ’s premium valuation relative to competitors such as Merck and AbbVie. JNJ Stock Has a New Growth Story
• Negative Sentiment: Analyst caution and valuation risk: Erste Group Bank downgraded JNJ from “buy” to “hold.” Commentary also notes that the stock’s elevated valuation could constrain returns, particularly as Treasury yields near 5% make government bonds more competitive with dividend stocks. Erste Group Bank Ratings

Wall Street Analyst Weigh In

JNJ has been the subject of a number of research analyst reports. Wall Street Zen cut Johnson & Johnson from a "buy" rating to a "hold" rating in a report on Saturday, August 1st. Freedom Capital upgraded Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 16th. UBS Group set a $270.00 price target on Johnson & Johnson in a research note on Wednesday, October 14th. Erste Group Bank cut Johnson & Johnson from a "buy" rating to a "hold" rating in a research report on Wednesday. Finally, Raymond James Financial set a $280.00 price objective on Johnson & Johnson in a research note on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, Johnson & Johnson has an average rating of "Moderate Buy" and an average price target of $275.92.

Johnson & Johnson Company Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.